Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Rare Tumor × sintilimab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Stomach Neoplasms 28 Carcinoma, Hepatocellular 26 Carcinoma, Non-Small-Cell Lung 20 Colorectal Neoplasms 13 Esophageal Squamous Cell Carcinoma 10 Lung Neoplasms 8 Nasopharyngeal Carcinoma 7 Rectal Neoplasms 6 Cholangiocarcinoma 6 Squamous Cell Carcinoma of Head and Neck 5 Pancreatic Neoplasms 4 Neoplasm Metastasis 4 Triple Negative Breast Neoplasms 3 Neoplasms 3 Lymphoma, Extranodal NK-T-Cell 3 Esophageal Neoplasms 3 Colonic Neoplasms 3 Carcinoma, Renal Cell 3 Breast Neoplasms 3 Uterine Cervical Neoplasms 2 Sarcoma 2 Nonsquamous Non-Small Cell Lung Cancer 2 Neuroendocrine Tumors 2 Lymphoma, Large B-Cell, Diffuse 2 Locally Advanced Rectal Cancer 2 Glioblastoma 2 Gastric Adenocarcinoma 2 Colorectal Cancer Metastatic 2 Carcinoma, Neuroendocrine 2 Carcinoma 2

Interventions

sintilimab 1 pyrotinib 1 palbociclib 1 niraparib 1 dacomitinib 1 aumolertinib 1 atezolizumab 1 alectinib 1 Vemurafenib 1 Imatinib Mesylate 1 Crizotinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04423185 2025-02-11

PLATFORM Study of Precision Medicine for Rare Tumors

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2 Recruiting

Rare Tumor

Data powered by HemOnc (CC BY 4.0) Colophon ⚡